(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds

I

Instylla

Status

Enrolling

Conditions

Arterial Bleeding in Solid Organs and Peripheral Arteries

Treatments

Device: Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter

Study type

Interventional

Funder types

Industry

Identifiers

NCT05364502
INY-P-21-002

Details and patient eligibility

About

To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.

Full description

A Prospective Multicenter Single-Arm Staged Study to Evaluate the Safety and Effectiveness of Embrace™ Hydrogel Embolic For Transcatheter Embolization of Arterial Bleeding in Solid Organs and Peripheral Arteries

Enrollment

118 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patients age ≥ 18 years old

Subjects who are candidates for transarterial catheter embolization with arterial bleeding documented on a suitable radiologic imaging and/or endoscopic visualization study taken during the index hospitalization that allows for the source of the arterial injury/bleeding to be localized. Includes (but not limited to) the following:

  • Non-variceal Upper Gastrointestinal (UGI) bleeds refractory to endoscopic treatment
  • End organ/visceral bleeds (kidney, liver and spleen including tumor bleeds)
  • Spontaneous hematoma (e.g., rectus sheath and psoas muscle hematomas)
  • Other peripheral arterial bleeds (e.g., pelvic hemorrhage) if not associated with risk of ischemia distal to the lesion or embolization of non-expendable arteries.
  • Subjects with at least one target vessel ≤6mm and Embrace HES can be delivered to the target vessel(s).
  • Subject is willing to comply with follow-up evaluation schedule.
  • No prior embolization in the target territory prior to study entry
  • The subject or a legally authorized representative has provided informed consent approved by the appropriate local IRB/EC.

Exclusion criteria

  • Life expectancy ≤ 30 days
  • In the Investigator's opinion, due to injury severity the subject is not likely to benefit from angioembolization (e.g., in the presence of significant polytrauma, multiple organ failure or shattered organs).
  • Any contraindication to arteriography or the embolization protocol utilized at treating institution.
  • Pregnant or breast-feeding (women of child-bearing potential must undergo a pregnancy test performed in accordance with local institutional requirements and agree to use contraception for at least six months).
  • Hemorrhagic shock (Class IV-see Appendix 1) at time of treatment
  • Target vascular territory supplied by the pulmonary artery, coronary artery, or cerebral or cerebellar artery (requiring embolization of these arteries) or the artery to be embolized has connections to these arteries via a collateral pathway.
  • Embolization for treatment of spinal arteries, lower GI bleeds, arteriovenous malformations, embolization of arteriovenous shunts, endoleak management, neurovascular bleeds, penetrating trauma of extremities.
  • Forrest Classification Type III UGI bleeds (see Appendix 2)
  • In the investigator's opinion, patient will require embolization of 4 or more discrete vascular territories/arterial injuries (requires that microcatheter be repositioned to discrete area) based on diagnostic angiography or another suitable imaging study.
  • Known or suspected angio-anatomical conditions that in the Investigator's opinion, would prevent the delivery catheter to gain access to the selected position for safe and intended embolization.
  • Known allergies (based on history) to PEG, ferrous compounds, tert Butyl Hydroperoxide, contrast media or procedural sedatives/anesthetics that is not amenable to pre-medication
  • Presence of medically relevant localized or systemic infection
  • The patient has other concurrent conditions or known history that in the opinion of the Investigator would be unlikely to receive clinical benefit from the study procedure or participation in the study may compromise patient safety or study objectives (including but not limited to ongoing acute infection, life-threatening concomitant trauma or conditions).
  • If known, enrollment in a concurrent study in which the study treatment may confound the evaluation of the study device.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

8

Loading...

Central trial contact

Rachel McElligott; Clinical Operations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems